
Larimar Therapeutics Advances Nomlabofusp Clinical Program with First Patient Dosed in Open Label Extension Study
BALA CYNWYD, PA — Clinical-stage biotechnology company Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the dosing of the first patient in an open label extension (OLE) study for its novel …
Larimar Therapeutics Advances Nomlabofusp Clinical Program with First Patient Dosed in Open Label Extension Study Read More